DK1459750T3 - (S,S)-rebexetin til behandling af fibromyalgi og andre somatoforme lidelser - Google Patents

(S,S)-rebexetin til behandling af fibromyalgi og andre somatoforme lidelser

Info

Publication number
DK1459750T3
DK1459750T3 DK04013382T DK04013382T DK1459750T3 DK 1459750 T3 DK1459750 T3 DK 1459750T3 DK 04013382 T DK04013382 T DK 04013382T DK 04013382 T DK04013382 T DK 04013382T DK 1459750 T3 DK1459750 T3 DK 1459750T3
Authority
DK
Denmark
Prior art keywords
rebexetine
fibromyalgia
treatment
somatoform disorders
somatoform
Prior art date
Application number
DK04013382T
Other languages
English (en)
Inventor
Saeeduddin Ahmed
Lars Birgerson
Pasquale Cetera
Robert Clyde Marshall
Robert Mcarthur
Duncan P Taylor
Erik H F Wong
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27495506&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1459750(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Application granted granted Critical
Publication of DK1459750T3 publication Critical patent/DK1459750T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DK04013382T 1999-07-01 2000-06-22 (S,S)-rebexetin til behandling af fibromyalgi og andre somatoforme lidelser DK1459750T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14196899P 1999-07-01 1999-07-01
US14413199P 1999-07-16 1999-07-16
US15825699P 1999-10-06 1999-10-06
US17038199P 1999-12-13 1999-12-13

Publications (1)

Publication Number Publication Date
DK1459750T3 true DK1459750T3 (da) 2005-08-15

Family

ID=27495506

Family Applications (4)

Application Number Title Priority Date Filing Date
DK05111704T DK1632234T3 (da) 1999-07-01 2000-06-22 (S,S)-reboxetin til behandling af kronisk træthedssyndrom
DK04013381T DK1459749T3 (da) 1999-07-01 2000-06-22 (S,S)-reboxetin til behandling af inkontinens
DK04013382T DK1459750T3 (da) 1999-07-01 2000-06-22 (S,S)-rebexetin til behandling af fibromyalgi og andre somatoforme lidelser
DK00941659T DK1196172T3 (da) 1999-07-01 2000-06-22 (S,S)-reboxetin til behandling af kronisk smerte

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK05111704T DK1632234T3 (da) 1999-07-01 2000-06-22 (S,S)-reboxetin til behandling af kronisk træthedssyndrom
DK04013381T DK1459749T3 (da) 1999-07-01 2000-06-22 (S,S)-reboxetin til behandling af inkontinens

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK00941659T DK1196172T3 (da) 1999-07-01 2000-06-22 (S,S)-reboxetin til behandling af kronisk smerte

Country Status (31)

Country Link
US (18) US6465458B1 (da)
EP (3) EP1196172B1 (da)
JP (3) JP2003503450A (da)
KR (5) KR100948757B1 (da)
CN (5) CN1289090C (da)
AR (1) AR035158A1 (da)
AT (9) ATE319453T1 (da)
AU (2) AU771258B2 (da)
BR (1) BR0012136A (da)
CA (2) CA2643231A1 (da)
CL (3) CL2008002867A1 (da)
CO (1) CO5190662A1 (da)
CZ (1) CZ299847B6 (da)
DE (9) DE60022916T2 (da)
DK (4) DK1632234T3 (da)
EA (6) EA200801805A1 (da)
ES (9) ES2242175T3 (da)
GE (1) GEP20094798B (da)
HK (2) HK1049630A1 (da)
HU (1) HUP0201623A3 (da)
IL (3) IL147246A0 (da)
MX (1) MXPA02000562A (da)
MY (1) MY137348A (da)
NO (4) NO20016406L (da)
NZ (2) NZ533243A (da)
PE (1) PE20010684A1 (da)
PL (1) PL196996B1 (da)
PT (5) PT1196172E (da)
SK (5) SK286668B6 (da)
TW (9) TWI294779B (da)
WO (1) WO2001001973A2 (da)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1632234T3 (da) * 1999-07-01 2007-09-17 Pharmacia & Upjohn Co Llc (S,S)-reboxetin til behandling af kronisk træthedssyndrom
CN100525761C (zh) * 1999-12-01 2009-08-12 Ucb公司 用于治疗cns疾病的吡咯烷乙酰胺衍生物或者其组合物
AU2001253114B2 (en) 2000-04-21 2005-08-25 Pharmacia & Upjohn Company Llc Compounds for treating fibromyalgia and chronic fatigue syndrome
CA2404704A1 (en) * 2000-04-21 2001-11-22 David W. Robertson Treatment of fibromyalgia and chronic fatigue syndrome
EP1333835A1 (en) * 2000-10-31 2003-08-13 Head Explorer A/S The use of selective noradrenaline reuptake inhibitors for the treatment of tension-type headache
CA2426069A1 (en) * 2000-11-15 2002-05-23 David Michelson Treatment of anxiety disorders
WO2002083141A1 (en) * 2001-04-17 2002-10-24 Pharmacia & Upjohn Company Treatment of fibromyalgia and chronic fatigue syndrome
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
GB0216027D0 (en) * 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
US20060167074A1 (en) * 2001-06-19 2006-07-27 Norbert Muller Methods and compositions for the treatment of psychiatric disorders
ATE452642T1 (de) * 2001-06-19 2010-01-15 Norbert Mueller Verwendung von cox-2 inhibitoren zur behandlung von affectiven störungen
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
ES2287338T3 (es) * 2001-11-30 2007-12-16 Eli Lilly And Company Uso de inhibidores de recaptacion de norepinefrina para el tratamiento de trastornos de tics.
HUP0402619A3 (en) * 2001-12-11 2008-04-28 Lilly Co Eli Use of norepinephrine reuptake inhibitors for the preparation of a medicament for treatment of cognitive failure
US20040102440A1 (en) * 2002-07-01 2004-05-27 Wong Erik Ho Fong Method of promoting smoking cessation
US20050096395A1 (en) * 2002-02-12 2005-05-05 Rao Srinivas G. Methods of treating attention deficit/hyperactivity disorder (adhd)
WO2003090743A1 (en) * 2002-04-24 2003-11-06 Cypress Bioscience, Inc. Prevention and treatment of functional somatic disorders, including stress-related disorders
KR101072885B1 (ko) 2002-05-17 2011-10-17 듀크 유니버시티 비만치료방법
AU2003227520B9 (en) * 2002-05-30 2008-06-26 Neurosearch A/S Triple monoamine reuptake inhibitors for the treatment of chronic pain
EP1515959B1 (en) * 2002-06-17 2009-08-12 Pfizer Italia S.r.l. Pharmaceutical salts of reboxetine
MY136318A (en) * 2002-07-25 2008-09-30 Pharmacia Corp Sustained-release tablet composition
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
MXPA05001705A (es) * 2002-08-14 2005-04-19 Pharmacia & Upjohn Co Llc Uso de reboxetina para el tratamiento de sofocos.
GB0219687D0 (en) 2002-08-23 2002-10-02 Lilly Co Eli Benzyl morpholine derivatives
US7384941B2 (en) 2002-08-23 2008-06-10 Eli Lilly And Company 2-(phenoxymethyl)-and 2-(phenylthiomethyl)-morpholine derivatives for use as selective norepinephrine reuptake inhibitors
ES2264028T3 (es) 2002-08-23 2006-12-16 Eli Lilly And Company Derivados de bencilmorfolina.
US20040106681A1 (en) * 2002-10-03 2004-06-03 Cypress Bioscience, Inc. Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders
US20040152710A1 (en) * 2002-10-15 2004-08-05 Deecher Darlene Coleman Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US20040180879A1 (en) * 2002-10-15 2004-09-16 Deecher Darlene Coleman Novel method of treating vasomotor symptoms
US7345096B2 (en) * 2002-10-15 2008-03-18 Wyeth Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
BRPI0406748A (pt) * 2003-01-13 2005-12-20 Dynogen Pharmaceuticals Inc Método de tratamento de náusea, vÈmito e ânsia de vÈmito ou qualquer combinação destes em um paciente que necessite do mesmo e composição farmacêutica
CA2512983A1 (en) * 2003-01-13 2004-07-29 Dynogen Pharmaceuticals, Inc. Method of treating functional bowel disorders
AU2004227945B2 (en) * 2003-04-04 2006-10-26 Dynogen Pharmaceuticals, Inc. Method of treating lower urinary tract disorders
ATE388698T1 (de) 2003-04-29 2008-03-15 Orexigen Therapeutics Inc Zusammensetzungen zur beeinflussung des gewichtsverlusts
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
WO2004100929A1 (en) 2003-05-12 2004-11-25 Synergia Pharma, Inc. Threo-dops controlled release formulation
WO2004105690A2 (en) * 2003-05-23 2004-12-09 Cypress Bioscience, Inc. Treatment of chronic pain associated with drug or radiation therapy
GB0319793D0 (en) * 2003-08-22 2003-09-24 Lilly Co Eli Pyridinylmorpholine derivatives
CA2536161A1 (en) * 2003-08-27 2005-03-10 Eli Lilly And Company Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors
WO2005025561A1 (en) * 2003-09-04 2005-03-24 Synergia Pharma, Inc. Compositions and methods for orthostatic intolerance
EP1663398B1 (en) * 2003-09-12 2009-11-25 Pfizer Limited Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline reuptake inhibitors
US7419980B2 (en) 2003-10-14 2008-09-02 Wyeth Fused-aryl and heteroaryl derivatives and methods of their use
US20050130987A1 (en) * 2003-10-14 2005-06-16 Wyeth Methods of treating vasomotor symptoms
US7491723B2 (en) 2003-10-14 2009-02-17 Wyeth Alkanol and cycloalkanol-amine derivatives and methods of their use
US7365076B2 (en) 2003-10-14 2008-04-29 Wyeth Substituted aryl cycloalkanol derivatives and methods of their use
US7531543B2 (en) 2003-10-14 2009-05-12 Wyeth Phenylpiperazine cycloalkanol derivatives and methods of their use
US7402698B2 (en) 2003-10-14 2008-07-22 Wyeth Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use
US7550485B2 (en) * 2003-10-14 2009-06-23 Wyeth Substituted N-heterocycle derivatives and methods of their use
US7524846B2 (en) 2003-10-14 2009-04-28 Wyeth Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use
GB0326148D0 (en) 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
ATE399557T1 (de) * 2003-12-12 2008-07-15 Lilly Co Eli Selektive norepinephrin-wiederaufnahmehemmer zur behandlung von hitzewallungen
EP1716126B1 (en) * 2003-12-23 2009-02-25 Eli Lilly And Company Morpholine derivatives as norepinephrine reuptake inhibitors
US7414052B2 (en) 2004-03-30 2008-08-19 Wyeth Phenylaminopropanol derivatives and methods of their use
US7517899B2 (en) * 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
GB0409744D0 (en) * 2004-04-30 2004-06-09 Pfizer Ltd Novel compounds
KR100871272B1 (ko) * 2004-04-30 2008-11-28 화이자 인코포레이티드 모폴린 화합물
JP4185154B2 (ja) * 2004-04-30 2008-11-26 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 中枢神経系障害治療用の置換モルホリン化合物
RU2006143659A (ru) * 2004-06-09 2008-06-20 Пфайзер Инк. (Uпфайзер Инк. (Us)S) Применение ребоксетина для лечения боли
US7244765B2 (en) * 2004-06-25 2007-07-17 Cytokine Pharmasciences, Inc Guanylhydrazone salts, compositions, processes of making and methods of using
CN101884626A (zh) 2004-08-13 2010-11-17 贝林格尔.英格海姆国际有限公司 包含普拉克索或其可药用盐的延长释放片剂、其制备方法及用途
US20080261955A1 (en) * 2004-10-01 2008-10-23 Timothy Dinan Use of Pharmaceutical Compositions of Lofepramine for the Treatment of Adhd, Cfs, Fm and Depression
WO2006105117A2 (en) * 2005-03-28 2006-10-05 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
PT2135603E (pt) 2005-11-22 2013-04-03 Orexigen Therapeutics Inc Composições e métodos para aumentar a sensibilidade à insulina
US20070253994A1 (en) * 2006-04-28 2007-11-01 Medtronic, Inc. Intraspinal Drug Delivery Methods and Devices To Alleviate Chronic Pelvic Pain
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
PT1948155E (pt) * 2006-06-28 2012-06-15 Chelsea Therapeutics Inc Composições farmacêuticas contendo droxidopa
KR20090090316A (ko) 2006-11-09 2009-08-25 오렉시젠 세러퓨틱스 인크. 체중 감량 약물을 투여하기 위한 단위 용량 팩키지 및 투여 방법
ES2480966T3 (es) 2007-03-09 2014-07-29 Chelsea Therapeutics, Inc. Droxidopa y composición farmacéutica de la misma para el tratamiento de la fibromialgia
WO2008122019A1 (en) * 2007-04-02 2008-10-09 Cypress Biosciences, Inc. Improving the tolerability of both mirtazapine and reboxetine by using them in combination
US20080275131A1 (en) * 2007-04-30 2008-11-06 Adolor Corporation Compositions of (-)-e-10-oh-nt and methods for their synthesis and use
NZ581707A (en) * 2007-05-07 2011-05-27 Chelsea Therapeutics Inc Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
US20090233959A1 (en) * 2008-02-19 2009-09-17 Adolor Corporation Beloxepin and analogs for the treatment of pain
US20090233957A1 (en) * 2008-02-19 2009-09-17 Adolor Corporation (-)-beloxepin and methods for its synthesis and use
US8956642B2 (en) 2008-04-18 2015-02-17 Medtronic, Inc. Bupivacaine formulation in a polyorthoester carrier
US8940315B2 (en) 2008-04-18 2015-01-27 Medtronic, Inc. Benzodiazepine formulation in a polyorthoester carrier
JP2011521973A (ja) 2008-05-30 2011-07-28 オレキシジェン・セラピューティクス・インコーポレーテッド 内臓脂肪の状態を処置するための方法
TWI438190B (zh) 2008-07-24 2014-05-21 Theravance Inc ３－（苯氧基苯基甲基）吡咯啶化合物
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
WO2010044016A1 (en) * 2008-10-17 2010-04-22 Pfizer Limited Novel uses for esreboxetine and racemic reboxetine
US20100267743A1 (en) * 2009-04-15 2010-10-21 Stangeland Eric L 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds
JP5826173B2 (ja) * 2009-07-13 2015-12-02 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ３−フェノキシメチルピロリジン化合物
EP2456436B1 (en) * 2009-07-21 2014-06-25 Theravance, Inc. 3-phenoxymethylpyrrolidine compounds
KR20120124423A (ko) 2010-01-11 2012-11-13 오렉시젠 세러퓨틱스 인크. 주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법
WO2012051103A1 (en) 2010-10-11 2012-04-19 Theravance, Inc. Serotonin reuptake inhibitors
US8501964B2 (en) 2010-12-03 2013-08-06 Theravance, Inc. Serotonin reuptake inhibitors
JP5880913B2 (ja) 2011-05-17 2016-03-09 三郎 佐古田 パーキンソン病の体幹症状（姿勢反射異常）の治療剤
PT3730132T (pt) 2012-06-06 2022-08-16 Nalpropion Pharmaceuticals Llc Composição para utilização num método de tratamento de excesso de peso e obesidade em doentes com alto risco cardiovascular
US10526280B2 (en) 2014-11-13 2020-01-07 University of Pittsburgh—of the Commonwealth System of Higher Education (2-amino-4-(arylamino)phenyl carbamates
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
WO2021113163A1 (en) * 2019-12-03 2021-06-10 Axsome Therapeutics, Inc. Use of reboxetine to treat nervous system disorders
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
EP3693020A1 (en) * 2019-02-08 2020-08-12 Burmaster International Group GmbH Potassium enriched topical formulations for pain relief and sleep aid
KR20220108122A (ko) * 2019-12-03 2022-08-02 액섬 테라퓨틱스, 인크. 신경계 장애 치료를 위한 레복세틴의 용도

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3996934A (en) 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US4031894A (en) 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
IL56369A (en) 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
US4465458A (en) * 1980-03-19 1984-08-14 Matsushita Electric Industrial Co., Ltd. Apparatus for burning liquid fuel equipped with heating-type fuel vaporizer
GB8419683D0 (en) 1984-08-02 1984-09-05 Erba Farmitalia 3-substituted derivatives of 1-amino-2-hydroxy-propane
GB2167407B (en) 1984-11-22 1988-05-11 Erba Farmitalia Enantiomers of phenoxy derivatives of benzyl morpholine and salts thereof
US4596807A (en) 1985-03-26 1986-06-24 Serotonin Industries Of Charleston Method and compositions for controlling pain, depression and sedation
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
CA2061665C (en) 1991-02-25 2002-04-16 Mark Mortensen Foreman Treatment of lower urinary tract disorders
US5281624A (en) 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
US5192751A (en) 1992-07-24 1993-03-09 Eli Lilly And Company Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence
TW344661B (en) 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
IL111786A0 (en) 1993-12-01 1995-01-24 Max Planck Gesellschaft Methods of promoting the survival and differentiation of subclasses of cholinergic and serotonergic neurons using fibroblast growth factor-5
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
ZA958725B (en) 1994-10-20 1997-04-16 Lilly Co Eli Treatment of disorders with duloxetine
EP0906104A4 (en) 1996-03-25 2003-12-10 Lilly Co Eli PAIN TREATMENT PROCESS
CA2250187A1 (en) 1996-03-25 1997-10-02 Eli Lilly And Company Composition comprising olanzapine and a drug useful in the treatment of pain for use in the treatment of pain
US5914333A (en) * 1996-07-31 1999-06-22 Novo Nordisk A/S Treatment of psychotic disorders
US6479074B2 (en) 1996-10-24 2002-11-12 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
US6572880B2 (en) 1996-10-24 2003-06-03 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
US20020015713A1 (en) 1996-10-24 2002-02-07 Murdock Robert W. Methods and transdermal compositions for pain relief
US6290986B1 (en) 1996-10-24 2001-09-18 Pharmaceutical Applications Associates, Llc Method and composition for transdermal administration of pharmacologic agents
DK0856312T3 (da) 1996-11-27 1999-06-23 Pfleger R Chem Fab Anvendelse af trospiumchlorid til fremstilling af et lægemiddel til behandling af blæresygdomme
KR20000057548A (ko) 1996-12-13 2000-09-25 알프레드 엘. 미첼슨 광학적 전송물질 및 결합재
WO1998046227A1 (en) 1997-04-11 1998-10-22 Eli Lilly And Company Composition for treating pain
US5942530A (en) 1997-08-28 1999-08-24 Eli Lilly And Company Method for treating pain
AU5155198A (en) 1997-08-28 1999-03-22 Robert Murdock Method and composition for transdermal administration of pharmacologic agent
US6622036B1 (en) * 2000-02-09 2003-09-16 Cns Response Method for classifying and treating physiologic brain imbalances using quantitative EEG
UA56257C2 (uk) 1997-09-23 2003-05-15 Елі Ліллі Енд Компані Спосіб лікування неадекватної визивної поведінки
WO1999015177A1 (en) 1997-09-23 1999-04-01 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
UA57107C2 (uk) 1997-09-23 2003-06-16 Елі Ліллі Енд Компані Спосіб лікування розладу поведінки
EP0919234A3 (en) 1997-10-17 1999-08-25 Eli Lilly And Company Potentiation of pharmaceuticals by moxonidine
US6586427B2 (en) * 1998-04-09 2003-07-01 Pharmacia & Upjohn Company Treatments for nervous disorders
NZ507398A (en) 1998-04-09 2004-01-30 Upjohn Co New treatments for nervous disorders
IT1305322B1 (it) * 1998-04-23 2001-05-04 Pharmacia & Upjohn Spa Uso di reboxetina per il trattamento di disturbi nervosi
EA003469B1 (ru) 1998-05-08 2003-06-26 Фармация Энд Апджон Компани Новые лекарственные комбинации ингибиторов повторного поглощения норадреналина (иппна), предпочтительно ребоксетина и пиндолола
SK20012000A3 (sk) 1998-06-29 2001-08-06 Pharmaceuticals Applications Asociates, Llc Transdermálny prostriedok na zmiernenie bolesti
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
DK1632234T3 (da) * 1999-07-01 2007-09-17 Pharmacia & Upjohn Co Llc (S,S)-reboxetin til behandling af kronisk træthedssyndrom
GB2355191A (en) * 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
SE9904750D0 (sv) 1999-12-23 1999-12-23 Pharmacia & Upjohn Ab New formulation, use and method
CN1396829A (zh) 2000-02-24 2003-02-12 法玛西雅厄普约翰美国公司 新的药物联合形式
US20050096349A1 (en) * 2003-11-03 2005-05-05 University Of Florida Methods to prevent or ameliorate medication-, procedure-or stress-induced cognitive and speech dysfunction and methods to optimize cognitive and speech functioning

Also Published As

Publication number Publication date
US7723334B2 (en) 2010-05-25
WO2001001973A3 (en) 2002-01-17
US7317011B2 (en) 2008-01-08
CA2643231A1 (en) 2001-01-11
DE60022916D1 (de) 2006-02-09
EA200801805A1 (ru) 2008-12-30
US6465458B1 (en) 2002-10-15
KR100704319B1 (ko) 2007-04-09
TW200607511A (en) 2006-03-01
TWI298255B (en) 2008-07-01
CA2375908A1 (en) 2001-01-11
US7241762B2 (en) 2007-07-10
CN1289090C (zh) 2006-12-13
EA200501496A1 (ru) 2006-06-30
NZ515885A (en) 2004-08-27
US7338953B2 (en) 2008-03-04
WO2001001973A2 (en) 2001-01-11
NO20016406D0 (no) 2001-12-28
US20020061910A1 (en) 2002-05-23
KR20020015363A (ko) 2002-02-27
TWI298254B (en) 2008-07-01
KR100717660B1 (ko) 2007-05-15
DE60019473T2 (de) 2006-02-23
EA200801806A1 (ru) 2008-12-30
MXPA02000562A (es) 2002-07-02
CL2008002866A1 (es) 2009-01-09
US20060128705A1 (en) 2006-06-15
EA200200111A1 (ru) 2002-06-27
WO2001001973A8 (en) 2001-05-17
CN1660110A (zh) 2005-08-31
NO20091158L (no) 2002-02-19
ATE292971T1 (de) 2005-04-15
DK1459749T3 (da) 2006-01-09
JP2003503450A (ja) 2003-01-28
CZ20014625A3 (cs) 2002-08-14
AU2004202096A1 (en) 2004-06-10
US20060135521A1 (en) 2006-06-22
ES2246485T3 (es) 2006-02-16
ATE296634T1 (de) 2005-06-15
US6610690B2 (en) 2003-08-26
SK286668B6 (sk) 2009-03-05
HK1049630A1 (en) 2003-05-23
TW200407146A (en) 2004-05-16
CN1205935C (zh) 2005-06-15
ES2247572T3 (es) 2006-03-01
ES2246487T3 (es) 2006-02-16
KR20090087134A (ko) 2009-08-14
DE60022692D1 (de) 2005-10-20
DE60022692T2 (de) 2006-06-22
CL2008002868A1 (es) 2009-01-09
DE60035232T2 (de) 2008-02-14
ES2242175T3 (es) 2005-11-01
US7276503B2 (en) 2007-10-02
US20060135520A1 (en) 2006-06-22
DE60023043T2 (de) 2006-06-14
JP2006143749A (ja) 2006-06-08
PT1632234E (pt) 2007-07-09
TWI245631B (en) 2005-12-21
DE60019473D1 (de) 2005-05-19
EP2087892A3 (en) 2009-09-30
SK286669B6 (sk) 2009-03-05
US20090247528A1 (en) 2009-10-01
TW200607510A (en) 2006-03-01
ATE320257T1 (de) 2006-04-15
PT1459750E (pt) 2005-08-31
PL352252A1 (en) 2003-08-11
DE60026627T2 (de) 2007-02-01
AU2004202096B2 (en) 2005-10-20
HUP0201623A3 (en) 2004-12-28
CL2008002867A1 (es) 2009-01-09
US20080096890A1 (en) 2008-04-24
US20040147614A1 (en) 2004-07-29
ATE305788T1 (de) 2005-10-15
CN1660111A (zh) 2005-08-31
NO20091168L (no) 2002-02-19
US6642235B2 (en) 2003-11-04
PT1459751E (pt) 2005-11-30
CN1660108A (zh) 2005-08-31
CN1660109A (zh) 2005-08-31
PT1196172E (pt) 2006-05-31
SK286667B6 (sk) 2009-03-05
US20030040464A1 (en) 2003-02-27
BR0012136A (pt) 2002-06-11
SK286104B6 (sk) 2008-03-05
CN1379672A (zh) 2002-11-13
ES2258010T3 (es) 2006-08-16
NO20016406L (no) 2002-02-19
TW200607509A (en) 2006-03-01
TWI294779B (en) 2008-03-21
KR100948757B1 (ko) 2010-03-23
US20060264436A1 (en) 2006-11-23
EP1196172B1 (en) 2006-03-15
AR035158A1 (es) 2004-05-05
EA200400589A1 (ru) 2004-12-30
KR20090087135A (ko) 2009-08-14
NZ533243A (en) 2005-12-23
KR20060099544A (ko) 2006-09-19
US20060142289A1 (en) 2006-06-29
US20080103147A1 (en) 2008-05-01
JP2006321815A (ja) 2006-11-30
DE60023043D1 (de) 2006-02-16
IL147246A0 (en) 2002-08-14
PE20010684A1 (es) 2001-06-24
CZ299847B6 (cs) 2008-12-10
US6703389B2 (en) 2004-03-09
US20080103146A1 (en) 2008-05-01
AU5633700A (en) 2001-01-22
ATE305307T1 (de) 2005-10-15
EA006652B1 (ru) 2006-02-24
KR100935277B1 (ko) 2010-01-06
NO20091159L (no) 2002-02-19
ATE319453T1 (de) 2006-03-15
SK286864B6 (sk) 2009-06-05
DE60022917D1 (de) 2006-02-09
ES2285645T3 (es) 2007-11-16
MY137348A (en) 2009-01-30
KR20050053799A (ko) 2005-06-08
US20020128173A1 (en) 2002-09-12
SK19382001A3 (sk) 2002-07-02
ES2239311T3 (es) 2005-09-16
ATE304358T1 (de) 2005-09-15
EA011094B1 (ru) 2008-12-30
EP2087892A2 (en) 2009-08-12
TW200607512A (en) 2006-03-01
HK1076723A1 (en) 2006-01-27
DE60020613T2 (de) 2006-03-16
TW200920378A (en) 2009-05-16
EA008381B1 (ru) 2007-04-27
CA2375908C (en) 2006-05-30
ATE305306T1 (de) 2005-10-15
EA200700232A1 (ru) 2007-06-29
EP1196172A2 (en) 2002-04-17
HUP0201623A2 (en) 2002-09-28
EA005029B1 (ru) 2004-10-28
EP2090312A1 (en) 2009-08-19
ATE364386T1 (de) 2007-07-15
CO5190662A1 (es) 2002-08-29
DE60020613D1 (de) 2005-07-07
IL187512A0 (en) 2008-06-05
AU771258B2 (en) 2004-03-18
ES2258251T3 (es) 2006-08-16
GEP20094798B (en) 2009-10-26
DE60035232D1 (de) 2007-07-26
US6987107B2 (en) 2006-01-17
DE60022916T2 (de) 2006-07-06
PL196996B1 (pl) 2008-02-29
TW200914027A (en) 2009-04-01
IL187513A0 (en) 2008-06-05
PT1459748E (pt) 2005-08-31
TW200922594A (en) 2009-06-01
DE60026627D1 (de) 2006-05-04
DK1196172T3 (da) 2006-06-19
US20020086864A1 (en) 2002-07-04
US20040058925A1 (en) 2004-03-25
DE60026704T2 (de) 2006-10-19
US20020107249A1 (en) 2002-08-08
TWI293250B (en) 2008-02-11
DE60026704D1 (de) 2006-05-11
DE60022917T2 (de) 2006-06-29
US20080103145A1 (en) 2008-05-01
ES2246488T3 (es) 2006-02-16
DK1632234T3 (da) 2007-09-17

Similar Documents

Publication Publication Date Title
DK1459750T3 (da) (S,S)-rebexetin til behandling af fibromyalgi og andre somatoforme lidelser
DK1063990T3 (da) Anvendelse af Biochanin-beriget ekstrakt til behandling af östrogen-associerede lidelser
IS6806A (is) Samsetningar af lyfjum (t.d. klórprómasíni og pentamídíni) fyrir meðhöndlun á æxlistruflunum
DK1352897T3 (da) Adamantanderivater til behandlingen af inflammatoriske sygdomme, immunsygdomme og cardiovaskulære sygdomme
DK1156813T3 (da) Reovirus til behandling af cellulære proliferative lidelser
DK1147083T3 (da) Arylpiperazinyl-cyclohexylindolderivater til behandling af depression
IS5720A (is) Latar gegn peptídýli af VLA-4 skilyrtri frumutengingu gagnlegir til meðhöndlunar á bólguvaldandi-, sjálfónæmis, og öndunarsjúkdómum
DK1144395T3 (da) 2-amino-benzoxazinon-derivater til behandling af fedme
NO20012158D0 (no) Substituerte 2-fenylbenzimidazoler, fremgangsmåte til fremstilling og anvendelse derav
DK1212317T3 (da) Indolderivater og anvendelse deraf til behandling af osteoporose blandt andre anvendelser
DK1228032T3 (da) Præparater, som indeholder hydroxyicosatetraensyrederivater, og fremgangsmåder til anvendelse ved behandling af öjentörhedslidelser
DK1228028T3 (da) Hydroxyicosatetraenoatsalte, præparater og fremgangsmåder til anvendelse til behandling af öjentörhedslidelser
DK1383733T3 (da) Fremgangsmåde til fremstilling af 1,3-substituerede indener og aryl-sammenföjede azapolycykliske forbindelser
DK1206436T3 (da) Retinoider til behandling af emfysem
DK2189162T3 (da) Fremgangsmåder til behandling af cellulære proliferative forstyrrelser
DK199800837A (da) Anlæg til behandling af emner
DK1381382T3 (da) Fremgangsmåder og præparater til behandling af öjensygdomme
DK1355936T3 (da) Polymerkonjugater af neublastin og fremgangsmåder til anvendelse af samme
DK1105390T3 (da) Imidazo(1,2a)pyridinderivater til behandling af gastrointestinale sygdomme
NO20052264D0 (no) Pregahalinderivater for behandling av fibromyalgi og andre forstyrrelser
DK1434588T3 (da) 2-(amino-3,4-dioxo-1cyclobuten-1-yl)aminoalkylsyrederivater til behandling af smerte
DK1530462T3 (da) 1-phenyl-2-dimethylaminomethylcyclohexanforbindelser til behandling af depressionssymtomer. smerte og inkontinens
DK1309322T3 (da) Anvendelse af 3-benzoylphenyleddikesyrederivater til behandling af retinale lidelser
DK1268482T3 (da) Pyranoindoler til behandling af glaukom
DK1500395T3 (da) Reboxetin til behandling af fibromyalgi og andre somatoforme lidelser